<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435278</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/017011</org_study_id>
    <nct_id>NCT01435278</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Glucosanol in Maintaining Body Weight</brief_title>
  <official_title>Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, there is no clinical evidence on the efficacy and safety of Glucosanol in&#xD;
      maintaining weight loss beyond the study duration of 12 weeks. The rationale for this&#xD;
      open-label study is to assess the efficacy in preventing regain of loss body weight and&#xD;
      safety of Glucosanol in subjects who are overweight or obese over a longer period after the&#xD;
      initial weight loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measured in kg using a calibrated scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumference (cm)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index, BMI (kg/m2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat content and fat free mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on appetite, hunger and food cravings</measure>
    <time_frame>24 weeks</time_frame>
    <description>The Control of Eating Questionnaire (COEQ) is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeling of satiety</measure>
    <time_frame>24 weeks</time_frame>
    <description>A 4-point categorical scale is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the efficacy of Glucosanol by the subjects</measure>
    <time_frame>24 weeks</time_frame>
    <description>A 4-point categorical scale is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
    <time_frame>24 weeks</time_frame>
    <description>Done at baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry parameter</measure>
    <time_frame>24 weeks</time_frame>
    <description>Done at baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measured in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of the safety of Glucosanol by the subjects</measure>
    <time_frame>24 weeks</time_frame>
    <description>A 4-point categorical scale is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of the safety of Glucosanol by the investigators</measure>
    <time_frame>24 weeks</time_frame>
    <description>A 4-point categorical scale is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>All reported adverse events, regardless of causality, will be recorded in the source documents and case report forms</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Glucosanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glucosanol</intervention_name>
    <description>2 tablets taken 3 times a day.</description>
    <arm_group_label>Glucosanol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously enrolled in, complied with, and completed the INQ/K/003411 (Glucosanol&#xD;
             weight loss) study, with weight loss of at least 3% of baseline body weight&#xD;
&#xD;
          -  Age 18 to 60 years at the time of inclusion into the INQ/K/003411 study&#xD;
&#xD;
          -  BMI between 25-35 at the time of inclusion into the INQ/K/003411 study&#xD;
&#xD;
          -  Expressed desire for weight maintenance&#xD;
&#xD;
          -  Accustomed to 3 main meals per day&#xD;
&#xD;
          -  Commitment to avoid the use of other weight loss products during study&#xD;
&#xD;
          -  Females' agreement to use appropriate birth control methods during the active study&#xD;
             period&#xD;
&#xD;
          -  Subject declares in writing his/her consent to participate, understands requirements&#xD;
             of the study and is willing to comply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to the ingredients of the device (Phaseolus vulgaris or members of&#xD;
             the Fabaceae family)&#xD;
&#xD;
          -  History of diabetes mellitus â€¢ Fasting blood glucose more than 7 mmol/L&#xD;
&#xD;
          -  History or clinical signs of endocrine disorders which may influence body weight (e.g.&#xD;
             Cushing's disease, thyroid gland disorders)&#xD;
&#xD;
          -  Clinically relevant excursions of safety parameter&#xD;
&#xD;
          -  Current use of anti-depressants&#xD;
&#xD;
          -  Presence of acute or chronic gastrointestinal disease (e.g. IBD, coeliac disease,&#xD;
             pancreatitis)&#xD;
&#xD;
          -  Uncontrolled hypertension (more than 160/110 mm Hg)&#xD;
&#xD;
          -  Stenosis in the GI tract&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Abdominal surgery within the last 6 months prior to enrollment&#xD;
&#xD;
          -  History of eating disorders like bulimia, anorexia nervosa within the past 12 months&#xD;
&#xD;
          -  Other serious organ or systemic diseases such as cancer&#xD;
&#xD;
          -  Any medication that could influence GI functions such as antibiotics, laxatives,&#xD;
             opioids, glucocorticoids, anticholinergics, or anti-diarrheals&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Any medication or use of products for the treatment of obesity (e.g. Orlistat, other&#xD;
             fatbinder, carb/starch blocker, fatburner, satiety products etc.)&#xD;
&#xD;
          -  More than 3 hours strenuous sport activity per week&#xD;
&#xD;
          -  History of abuse of drugs, alcohol or medication&#xD;
&#xD;
          -  Smoking cessation within 6 months prior to enrolment&#xD;
&#xD;
          -  Inability to comply due to language difficulties&#xD;
&#xD;
          -  Presence of other factor(s) that, in the investigator's judgement, should preclude&#xD;
             subject participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barbara Grube, MD</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight maintenance</keyword>
  <keyword>BMI</keyword>
  <keyword>Body weight</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <keyword>Satiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

